I wish. FWIW, i've emailed Amarin IR asking for clarification about the MITIGATE trial and KM's comments about "real world evidence" at the JPM conference. Will post here if I get any reply.
For the primary endpoints, the followup period is a "minimum of 6 months and up to 12 months" (Dr. Ambrosy stated this in the June 2021 webcast). Nobody knows for sure what happens after the 12 month period, if participants are offered to stay on Vascepa or not, which is rather strange since everyone in that trial qualified for and should have been on Vascepa to begin with.
Market Data 
Markets 
AI
